Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: A nationwide cohort study

BMJ Open

Volumn 7, Issue 6, 2017, Pages

  Lamb, F ^a   Herweijer, E ^a   Ploner, A ^a   Uhnoo, I ^b   Sundstrom K ^a   Sparen P ^a   Arnheim Dahlstrom L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

epidemiology; infectious diseases; preventive medicine; public health

Indexed keywords

CANCER VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CHILD; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONDYLOMA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; PROPHYLAXIS; SENSITIVITY ANALYSIS; SOCIAL STATUS; SWEDEN; VACCINATION; VACCINE IMMUNOGENICITY; CONDYLOMA ACUMINATUM; IMMUNIZATION; INCIDENCE; PAPILLOMAVIRUS INFECTION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SWEDEN; YOUNG ADULT;

EID: 85020640782     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-015021     Document Type: Article

References (31)

1. Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis 2015;211.
2. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013;309:1793-802.
3. Lazcano-Ponce E, Stanley M, Muñoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014;32:725-32.
4. Neuzil KM, Canh DG, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011;305:1424-31.
5. Romanowski B, Schwarz TF, Ferguson LM, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014;10:1155-65.
6. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011;7:1374-86.
7. WHO. Human papillomavirus vaccines: who position paper,. 2014 http://www.who. int/wer/2014/wer8943.pdf? ua= 1.
8. European Medicines Agency. Assessment report Gardasil, 2014.
9. Blomberg M, Dehlendorff C, Sand C, et al. Dose-Related differences in effectiveness of Human Papillomavirus vaccination against Genital warts: a Nationwide study of 550,000 Young girls. Clin Infect Dis 2015;61:676-82.
10. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.
11. World Health Organisation. International classification of disease. Tenth Revision 2010.
12. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a swedish national cohort study. J Natl Cancer Inst 2013;105:469-74.
13. Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014;311:597-603.
14. Jensen KE, Munk C, Sparen P, et al. Women's sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand 2011;90:459-67.
15. Donken R, Knol MJ, Bogaards JA, et al. Inconclusive evidence for non-inferior immunogenicity of two-compared with three-dose HPV immunization schedules in preadolescent girls: a systematic review and meta-analysis. J Infect 2015;71:61-73.
16. Hernández-Ávila M, Torres-Ibarra L, Stanley M, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother 2016;12:30-8.
17. Krajden M, Cook D, Yu A, et al. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 2014;32:624-30.
18. Romanowski B, Schwarz TF, Ferguson L, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother 2016;12:20-9.
19. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res 2013;6:1242-50.
20. Mariani L, Vici P, Suligoi B, et al. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther 2015;32:10-30.
21. Bogaards JA, Berkhof J. Assessment of herd immunity from human papillomavirus vaccination. Lancet Infect Dis 2011;11:896-7.
22. Donken R, Bogaards JA, van der Klis FR, et al. An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls. Hum Vaccin Immunother 2016;12:1381-93.
23. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011;11:39-44.
24. Smith MA, Liu B, McIntyre P, et al. Fall in genital warts diagnoses in the general and indigenous australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis 2015;211:91-9.
25. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:g1458.
26. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a populationbased HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227.
27. Herweijer E, Sundström K, Ploner A, et al. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study. Int J Cancer 2016;138:2867-74.
28. Svahn MF, Munk C, von Buchwald C, et al. Burden and incidence of human papillomavirus-associated cancers and precancerous lesions in Denmark. Scand J Public Health 2016;44:551-9.
29. Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the Quadrivalent Human Papillomavirus Vaccine: a Systematic Review of 10 years of Real-world experience. Clin Infect Dis 2016;63:519-27.
30. Herweijer E, et al. Population-Based Cohort Study. PLoS One 2015;10:e0134185.
31. Jit M, Brisson M, Laprise JF, et al. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2015;350:g7584.